These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 18194597)

  • 21. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
    Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
    J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
    Cao QW; Li HY; Yao XX; Wang JF
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
    De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C
    J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
    Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
    Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma.
    Zizhen Z; Hui C; Yanying S; Danping S; Jiahua L; Chao H; Xingzhi N
    Pathol Oncol Res; 2013 Apr; 19(2):317-22. PubMed ID: 23239192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
    Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
    Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of 3q27 chromosomal abnormality in diffuse large B cell lymphoma using FISH on cell microarray].
    Jiang HY; Li HL; Zhao T
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):73-7. PubMed ID: 18247310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.
    Hirose Y; Masaki Y; Karasawa H; Shimoyama K; Fukushima T; Kawabata H; Ogawa N; Wano Y; Ozaki M
    Int J Hematol; 2005 Jan; 81(1):48-57. PubMed ID: 15717689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
    Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J
    Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.